Vedolizumab—A Case Example of Using Quantitative Pharmacology in Developing Therapeutic Biologics in Inflammatory Bowel Disease
Maria Rosario(Millennium Engineering and Integration (United States)), Irving H. Fox(Takeda (United States)), Catherine Scholz(Kura Oncology (United States)), Nathanael L. Dirks(Metrum Research Group (United States)), Asit Parikh, Diane R. Mould(Phoenixville Hospital), Timothy Wyant(University of Maryland, Baltimore)
Cited by 1
Related Papers
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
|Gastroenterology|2014|714
Treatment of Ulcerative Colitis with a Humanized Antibody to the α <sub>4</sub> β <sub>7</sub> Integrin
|New England Journal of Medicine|2005|694